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AbstRAct
Therapies to prevent onset and progression of pulmonary arterial pressure are not very effective yet. This 
study was designed to investigate the effects of a novel dihydropyrimidinone, ethyl 4-(4′-heptanoyloxyphenyl)-6-
methyl-3,4-dihydropyrimidin-2-one-5-carboxylate (H-DHPM) on pathogenesis of monocrotaline (MCT)-induced 
pulmonary arterial hypertension (PAH). For the same purpose, rats were injected intraperitoneally (i.p.) a single dose 
(60 mg/kg) of MCT which led to development of PAH in 21 days. MCT insult caused high mortality, pulmonary 
vascular and parenchymal remodelling. Since the course of PAH pathogenesis is characterised by an early onset 
and progression phases, H-DHPM was administered i.p. at 30 mg/kg dosage in MCT pre-injected animals either 
from day 0 through day 21 or day 14 though day 21 of MCT injection in two separate treatment groups. H-DHPM 
significantly improved survival, prevented remodelling of pulmonary vasculature and parenchyma and subsequently 
ameliorated PAH pathogenesis. Moreover, we observed significant decrease in right ventricle hypertrophy, measured 
by wet weight of right ventricle (RV) divided by wet weight of left ventricle plus septum (LV+S), in H-DHPM treated 
groups as compared to MCT injected animals. These findings suggest H-DHPM not only prevented development 
of PAH but also treated the PAH pathogenesis in progressive phase. In conclusion, our data determines H-DHPM, 
might be a future drug for the prevention of PAH.
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NOMENcLAtURE
PH Pulmonary hypertension 
RVH Right ventricle hypertrophy
RVSP Right ventricle systolic pressure 
MCT Monocrotaline 
H-DHPM ethyl 4- (4′-heptanoyloxyphenyl)-6-methyl-3,4-
dihydropyrimidin-2-one-5-carboxylate
CCB Calcium channel blockers 
PVR Pulmonary vascular resistance
1. INtROdUctION
Pulmonary arterial hypertension (PAH), defined by a 
rise in mean pulmonary arterial pressure above 25 mmHg 
at rest, is a progressive disease characterised by pulmonary 
vasoconstriction and gradual precapillary arterial remodelling 
leading to pulmonary vascular resistance (PVR)1. Impedance 
in circulation by PVR leads to right ventricular remodelling, 
frequently terminating into right heart failure and premature 
mortality2,3. Vascular remodelling befalls predominantly due to 
pulmonary artery smooth muscle cell (PASMC) proliferation, 
migration and pulmonary artery endothelial cells (P-EC) 
dysfunction4,5. Various therapeutic strategies like vasodilators, 
diuretic therapy, inhaled nitric oxide therapy, intravenous 
prostacyclin, phosphodiesterase inhibitors, endothelin 
antagonists and anticoagulant agents have been employed to 
manage PAH.2 However, due to limited effectiveness, high cost 
and serious side effects, an appropriate therapy is still lacking. 
To achieve the goal of finding better therapeutic targets, the 
course of disease needs to be followed in order to evaluate the 
changes in early and progressive phases of PAH pathogenesis.
Monocrotaline (MCT), a pyrrolizidine alkaloid from 
Crotalaria plant, is bioactivated in liver to monocrotaline 
pyrrole (MCTP), which is a potent pneumotoxin6. Numerous 
researchers have established that a single dose of MCT 
(intraperitonealor subcutaneous) induces PAH in animals 
by pulmonary endothelial damage, medial hypertrophy of 
the pulmonary arteries, and subsequently right ventricular 
remodelling6. Recent evidences suggest MCT induces 
endothelial dysfunction and consequent pulmonary arterial 
hypertension, by binding to extra cellular calcium sensing 
receptor (CaSR)7. Calcium (Ca2+) channel pathway has been 
previously related to play a key role in vasoconstriction and 
remodelling of pulmonary vessels. Intracellular Ca2+[Ca2+]i acts Received : 02 October 2017, Revised : 06 December 2017
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as a secondary messenger and its imbalance can greatly influence 
pathophysiology of PAH by inducing PASMC proliferation and 
P-EC instability7. Calcium channel blockers (CCBs), which are 
a class of drugs that avert entry of Ca2+ into cardio myocytes, 
PASMC and P-EC, hence preclude contractility of heart and 
constriction of pulmonary arteries (PA)8-11 . Previously, long 
acting CCBs (dihydropryamidine) like nifedipine, diltiazem, 
nicardipine, felodipine and amlodipine have been used in 
ameliorating effects of increased Ca2+ insurgency into cytosol 
to treat pulmonary arterial remodelling9,12-16.
Dihydropyrimidinone (DHPM), a derivative of 
dihydropyrimidine and class of CCBs have antihypertensive 
effects; however, no established data is available on its use in 
treating PAH17. Of note, the structural modifications greatly 
influence function of pyrimidinones and recently, Munral16,18,  et 
al. synthesised a novel CCB, a modified DHPM, namely ethyl 
4-(4′-heptanoyloxyphenyl)-6-methyl-3,4-dihydropyrimidin-2-
one-5-carboxylate (H-DHPM). H-DHPM, a versatile CCB, has 
been reported to have better functional efficacy as compared 
to parent moiety OH-DHPM16,18. The activity of H-DHPM in 
blocking Ca2+ activity has been attributed by the authors to 
an acyl (heptonyl) group at C-4’ position of the compound. 
Priya18, et al. have reported H-DHPM as an effective CCB 
with antithrombotic activity. It has been further suggested in 
the study that H-DHPM has highest Ca2+ channel blocking 
capability as compared to other CCBs. Given the above 
mentioned rationale, in the present study, we investigated the 
beneficial effects of H-DHPM on MCT-induced PAH. 
2. MEtHOds
2.1 Animal Model and Experimental design 
All experiments were carried out on male adult Sprague-
Dawley rats (200 g to 250 g). The rats were housed in the 
experimental animal facility of the institute and on standard 
diet with deionised water (ad-libitum). All animal procedures 
were conducted in accordance with Committee for Purpose of 
Control and Supervision of Experimental Animals (CPCSEA), 
Government of India. 
In the current study, 15 animals were assigned to each 
group. Animals were categorised into groups as shown in Table 
1. The rationale for the decision of choosing the dosage was 
based upon publication of Priya18, et al., wherein they had used 
the drug at 52 mg/kg p.o. Drug (H-DHPM) was dissolved in 
DMSO (50 %v/v). H-DHPM was administered to rats either 
from day 0 of MCT injection or from 14 day of MCT injection 
as explained in Table 1.
2.2 chemicals and Reagents 
All Chemicals and reagents were purchased from Sigma-
Aldrich (uSA). Masson’s trichrome Stain (HT15-1kT) was 
purchased from Sigma Aldrich (uSA). ApopTag Red In Situ 
Apoptosis Detection kit (S7165) was purchased from Millipore 
(uSA). 
2.3 synthesis of H-dHPM
H-DHPM was synthesised as described previously at 
Department of Chemistry, university of Delhi, Delhi, India. 
The physical and chemical characteristics of the H-DHMP 
have been previously explained and were reproduced for 
present study16,18.
2.4.  Hemodynamic Measurements
After anesthetizing rats with 1.2 mg/kg (i,p,) urethane, rats 
were rested in supine position followed by making an incising 
on skin from mandible to sternum to expose the right jugular 
vein followed by bluntly nicking the vein. Right ventricular 
systolic pressure (RVSP) was measured by inserting a micro-
tip catheter (3.0 F, Millar Instruments, Houston, uSA) and 
passing it through jugular vein to right ventricle. RVSP was 
recorded and analysed by the Power Lab Data Acquisition 
system using Lab Chart 7 software (AD Instruments, Australia). 
The obtained results were plotted using  Prism5 (GraphPad San 
Diego, CA, uSA) for statistical analysis. After hemodynamic 
measurements were obtained, rats were euthanised with 
overdose of urethane (3 gms/kg; i.p.) 
2.5 Histology and Morphometry
After euthanizing, the rats were perfused with PBS 
followed by 4 per cent PFA. Heart and lungs were harvested 
en-bloc, hearts was separated from lungs. The right ventricle 
table 1. Animal grouping and dosing
Group designation dosage; Route day of dosage Regime of dosage
Control C N/A Nil N/A
Monocrotaline injected MCT 60 mg/kg; i.p. 1 day Single dose
Monocrotaline injected 
and  H-DHPM early dose
MCT+ED MCT: 60 mg/kg, 
H-DHPM: 30 mg/kg; i.p.
MCT: 1day, H-DHPM: 
daily for 21 days
12 h after MCT dose H-DHPM was given i.p.
H-DHPM was administered daily for 21 days
Monocrotaline injected 
and H-DHPM late dose
MCT+LD MCT: 60 mg/kg, 
H-DHPM: 30 mg/kg; i.p.
MCT: 1day, H-DHPM: 
daily for 7 days
14 days after MCT dose H-DHPM was given i.p.
H-DHPM was administered daily for 7 days
Dimethyl Sulphoxide 
injected
DMSO Proportional to treatment 
volume
21 days Daily
Study protocol
33
MALIk, et al.: DEF. LIFE SCI. J., VOL. 3, NO. 1, JANuARy 2018, DOI : 10.14429/dlsj.3.12005
(RV) was separated from the left ventricle (LV) plus ventricular 
septum and the wet weights were recorded. RV hypertrophy, 
determined by Fulton’s Index (FI), was expressed as the ratio of 
RV to LV plus ventricular septum (FI=RV/LV+S). Separately, 
lungs were instilled with 10 per cent formalin by tracheal 
installation and ligated with silk suture and left overnight. Left 
lung was dissected out and distal zone of left lung was prepared 
for paraffin embedding. 5 µm thick sections of paraffin-
embedded lung tissue were deparaffinised using xylene, 
followed by treatment with gradient ethanol and then washing 
with PBS. For histological analysis, tissues were stained with 
haematoxylin and eosin (H&E). For morphometery of distal 
pulmonary arteries, the medial wall thickness were measured 
in approximately 40 distal pulmonary arteries (between 25-
200µm) per animal. The average was calculated using the 
formula19.
For Masson’s trichrome staining (MTS), Trichrome Stain 
(Masson) kit (cat no. HT15, Sigma Aldrich) was used as per 
manufactures protocol and 40 images per group were captured 
and analysed. Olympus BX 51 (Olympus) microscope was 
used for imaging at magnification of 40 x, and quantification of 
expression (using pixel intensity) was performed with ImageJ 
software from the National Institutes of Health and statistically 
evaluated by GraphPad Prism5.
2.6 tUNEL Assay
Apoptosis in lung tissue was detected by deoxynucleotidyl 
transferase duTP nick end labeling (TuNEL) staining. 
ApopTag Red In-Situ Apoptosis Detection kit was used 
to detect apoptotic cells in lung tissues according to the 
manufacturer’s protocol. Briefly, 5µm thick sections of 
paraffin-embedded lung tissue were deparaffinised using 
xylene, followed by treatment with gradient ethanol and then 
washing with PBS. As a positive control (PC) of apoptotic 
cells, tissues were incubated in DNase I (0.5 ug/ml) for 10 min 
at room temperature. Slides were counterstained for 5 min 
in DAPI (4’,6-diamidino-2-phenylindole; a nuclear dye) and 
mounted. 10 views (images) per section at 40 x magnification 
were captured using Olympus BX51 (Olympus) microscope 
and analysed using ImageJ and statistically evaluated using 
Prism5 (GraphPad). Total number of TuNEL+ was single blind 
analysed to avoid any bias. TuNEL+positive nuclei relative 
to total DAPI stained nuclei were counted using ImageJ(NIH) 
software. 
2.7 statistical Analysis
All data reported as mean ± SEM. Statistical analysis 
was performed using  Prism5 software (GraphPad). Data 
were analysed between multiple groups by one-way analysis 
ANNOVA followed by Bonferroni’s post-hoc test p-value of 
<0.05 was considered statistically significant.
3. REsULts
3.1 beneficial Effects of H-dHPM on survival 
In MCT group, animals injected with MCT (60 mg/kg), 4 
out of 15 animals died by 21 days of MCT exposure. Animals 
in MCT+ED group (H-DHPM treatment from day 0 of MCT 
injection), showed no mortality whereas one animal died in 
MCT+LD group (H-DHPM treatment from day 14 of MCT 
injection) by 21 days. Furthermore animals in drug alone 
(H-DHPM) or in DMSO group all the animals survived. The 
survival index in relation to dosage is plotted by kaplan-Meier 
method using GraphPad  Prism5 in Fig. 1. 
Additionally, we also observed a decrease in weight of 
rats that were given MCT as compared to control whereas 
H-DHPM treated rats showed no significant change in body 
weight as compared to control as shown in Table 2. Similarly, 
rats injected with DMSO also showed no significant change in 
body weight. 
Figure 1. Effect of H-dHPM on Mct injected rats H-dHPM 
administered intraperitoneally (i.p.) at 30 mg/kg to 
Mct exposed rats at day 0 or day 14 significantly 
improved survival of rats as compared to Mct. After 
21 days, 100 per cent survivorship was observed in c, 
Mct+Ed, H-dHPM and dMsO where as 73.3 per 
cent survivorship was observed in Mct rats, 93.3 
per cent survivorship was observed in H-dHPM+Ld. 
n=15/group. survival graph was plotted using Kaplan-
Meier method and compared by Mantel-cox test. 
Using Prism5 (GraphPad). Mct vs c p<0.05.
3.2 H-dHPM significantly Improves Pulmonary 
Hemodynamics
The RVSP in control group (c; n=15) which did not 
receive any drug was (22.6 + 1.8 mmHg). There was a 
significant increase in RVSP in animals of group (n=11) that 
received MCT (46.2 ± 0.88 mmHg, p<0.05). Furthermore, 
rats treated with H-DHPM from day zero of MCT treatment, 
MCT+ED group (n=15), showed significant decrease in 
RVSP as compared to MCT (23.2 ± 1.45 mmHg). Similarly, 
rats treated with H-DHPM from day 14 of MCT injection, 
MCT+LD (n=14) also showed a significant decrease in RVSP 
as compared to MCT (25.3 ± 0.80 mmHg). Additionally, in 
H-DHPM group (n=15) which received H-DHPM drug alone 
(22.3 ± 1.2 mmHg) did show any significant changes in RVSP 
as compared to control. Likewise, animals treated with DMSO 
only, DMSO group (n=15), showed no significant change 
in RVSP (21.9 ± 0.8 mmHg) (Fig. 2(a)). MCT injection or 
H-DHPM or vehicle treatment had no effect on systemic blood 
pressure in all animals (data not shown).
RVH, a hallmark of PH, was assessed by in all animals. 
FI in rats of control group (C) was 0.36 ± 0.03 FI in MCT 
group rats was significantly increased (0.53±0.09, p<0.05) 
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as compared to control group (Fig. 2(b)). 
Moreover, in H-DHPM+ED group rats FI 
(0.39 ± 0.05) was significantly alleviated 
as compared to MCT group (Fig. 2(b)). 
Similarly, rats in H-DHPM+LD, FI (0.38 
± 0.02) was significantly decreased as 
compared to MCT group. Animals in 
H-DHPM alone group (0.37 ± 0.06) and 
DMSO group (0.39 ± 0.08) showed no 
significant change in FI as compared to 
control. These findings clearly suggested 
that 30 mg/kg dose of H-DHPM attenuated 
pulmonary hypertension and right heart 
remodelling induced by MCT. All values 
were plotted and statistically analysed 
using Prims5 (GraphPad).
3.3 H-dHPM prevents Pulmonary 
Arterial Medial Wall thickness
Another hallmark of progression of 
PH is the progressive increase in PVR, 
caused by the gradual increase in distal PA 
remodelling; which is assessed by calculating 
change in the arterial wall thickness by 
following % medial wall thickness (pMWT) 
= [(2xmedial thickness)/external diameter) 
x100].  Pulmonary arteries falling between 
diameters of 25 µm - 200 µm were analysed 
to quantify the medial wall thickness. 
We observed a significant increase in 
pMWT of MCT group rats (51.5±8.12 %, 
p<0.05) as compared to the control group 
rats (25.5±10.12%) as shown in Fig. 3(a). 
Animals in H-DHPM+ED group had 
significant decrease in (27.9±10.10%) as 
compared to MCT group as shown in Fig. 
3(a). Similarly, rats in H-DHPM+LD group 
Figure 2. H-dHPM improves pulmonary hemodynamics in Mct injected animals (a) Graphical representation of RVsP plotted and 
analysed by Prim5 (GraphPad), which showed a significant increase in RVsP of animals insulted with Mct (46.2 ± 0.88 
mmHg, *p<0.05 vs c) as compared to c (22.6+1.8 mmHg). RVsP in H-dHPM+Ed (23.2 ± 1.45 mmHg) and H-dHPM+Ld 
(25.3 ± 0.80 mmHg) H-dHPM (22.3 ± 1.2mmHg), dMsO (21.9 ± 0.8 mmHg)  was non-significant as compared to c and 
(b) RVH was measured as wet weight of RV and LV+s by  formula, RVH was highly significantly increased in Mct(0.53 
± 0.09 mmHg; *p<0.05 vs c)  as compared to c (0.36±0.03); whereas, non-significant H-dHPM+Ed (0.39 ± 0.05 mmHg), 
H-dHPM+Ld (0.38 ± 0.02 mmHg), H-dHPM (0.37 ± 0.06 mmHg) and dMsO (0.39± 0.08 mmHg) as compared to control. 
n=15/group in c/H-dHPM/Mct+Ed/dMsO; n=11 in Mct; n=14 in Mct+Ld.
Figure 3.  Preventive effect of H-dHPM on Mct induced pulmonary vascular 
remodelling (a) Arteries falling between 25 to 200µm of diameter were 
analysed using ImageJ and statistically analysed and plotted in Prism5 
(GraphPad). Percent medial wall thickness in Mct (51.5 ± 8.12%; *p<0.05 
vs c) group was significantly increased as compared to c (25.5 ± 10.12%). 
However, percent medial wall thickness in H-dHPM+Ed (27.9 ± 10.10%), 
H-dPM+Ld (33.7 ± 7.10%), H-dHPM (26.4 ± 10.1%) and dMsO (25.7 ± 
10.11%) were non-significant as compared to c. % medial wall thickness = 
[(2xmedial thickness)/external diameter) x100] in Prism5 (GraphPad) and 
(b) Representative H&E stained lung section images of different groups 
showing pulmonary artery remodelling. Images were captured by Olympus 
bX51 at 40x. scale bar is 50 µm, n=7/group.
(a) (b)
(a)
(b)
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also showed a significant decrease in pMWT (33.7 ± 7.10) as 
compared to MCT group. Rats in H-DHPM (26.4 ± 10.1) and 
DMSO (25.7 ± 10.11%) group showed no change in pMWT. 
Representative images of pulmonary arteries of all animal 
groups are shown in Fig 3(b). These observations suggest 
H-DHPM significantly prevented remodelling of dPA induced 
by MCT. For analysis, 40 images were captured at 40x using 
Olympus Bx51 microscope (Olympus) and analysed/measured 
by ImageJ (NIH). The measured values statistically analysed 
were plotted using Prism5 GaphPad (Fig. 3(b)). n=7/group.
3.4 Early or Late treatment with H-dHPM 
Prevented Pulmonary Parenchymal tissue 
Remodeling in Mct-induced PAH Animal Model
Lung has the major population of pulmonary parenchymal 
cells which form the milieu of all pulmonary vessels. Hence, 
it’s of paramount importance to assess the morphological 
changes in pulmonary parenchyma in the course of disease. 
To access the effect of MCT and H-DHPM on pulmonary 
parenchymal remodelling, tissue sections were either stained 
with haematoxylin-eosin or Masson’s trichrome stain. The 
former was used to assess the morphology of pulmonary 
parenchymal architecture, and later was used to assess the 
deposition of collagen in all groups. We observed, 21 days 
after MCT injection, the animals had developed a prominent 
structural remodelling in pulmonary parenchymal architecture 
which was attenuated by H-DHPM treatment in both groups 
H-DHPM+ED and H-DHPM+LD (Fig. 4(a)). Additionally we 
observed no prominent changes in pulmonary parenchymal 
architecture in H-DHPM or DMSO groups as compared to 
control (Fig. 4(a)). Moreover, we also observed increased 
intravascular infiltration, increased alveolar oedema and 
Figure 4. Pulmonary parenchymal remodelling regresses by treatment of H-dHPM in Mct injected rats (a) Representative images 
of H&E stained lung tissues showing prominent remodelling of alveolar architecture in Mct group. (b) Representation of 
Masson’s trichrome stained lung sections of rats. A marked increase of collagen deposition (blue colour) was observed in 
lung sections of Mct group, whereas no such observations were found in lung sections of H-dHPM treatment or dMsO 
groups. Images were taken at 40x by Olympus bX51 and analysed by ImageJ software. scale bar is 50 µm. Graphical 
representation of Mts stained sections showed 1.5 fold increase of collagen deposition in Mct lung sections only. Pixel 
intensity of blue color was calculated by ImageJ and plotted using Prism5 (GraphPad),  n=7/group.
(a)
(b)
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alveolar septal hyperplasia in rats insulted with MCT which 
was markedly mitigated by H-DHPM treatment. Furthermore, 
the MTS images showed a prominent collagen deposition 
(marked by blue colour) in lung tissues of MCT group animals 
as compared to control. On the contrary, animals in H-DHPM 
+ED and H-DHPM+LD groups had showed marked mitigated 
collagen deposition in lung tissues as compared to MCT 
group (Fig. 4(b)). The statistical evaluation of total collagen 
deposition was performed using ImageJ (NIH) and Prism5 
(Graphpad) which is shown in Fig 4(b), and collagen deposition 
is represented as fold change as compared to control. As shown 
in graph, MCT group animals showed significant increase 
in collagen deposition (1.5 fold, p<0.05) as compared to 
control, whereas no such significant changes were observed in 
H-DHPM+ED, H-DHPM+LD, H-DHPM and DMSO 
group as compared to control. (n=7/group)
3.5 H-dHPM Induces Apoptosis to Prevent 
Remodeling of Pulmonary Arteries and 
Parenchyma
Considering the effect of intracellular 
calcium concentration on vascular 
remodelling, we assayed pulmonary tissues 
for apoptosis by TuNEL assay represented in 
Fig. 5(a). We observed a very minimum number 
of cells underwent apoptosis in MCT (4.17±0.64) 
injected animals non-significant to control animals 
(2.3±0.51). However MCT animals treated with 
H-DHPM showed very marked increase in TuNEL 
positive cells in both H-DHPM+ED (41.56±5.03 
p<0.05) and H-DHPM+LD (37.43 ± 7.09, p<0.05). 
Treatment of control rats with either H-DHPM 
(3.7±1.65) or vehicle (3.53±1.85) showed no increase 
or decrease in TuNEL positive cells as compared to 
control rats. Dnase I treated tissue sections used as 
a positive control (PC) showed highest percentage 
of TuNEL positive cells (59.36 ± 4.50 , p<0.05). 
Representative images have been presented in 
Fig. 5(a) and graphically plotted in Fig. 5(b). TuNEL 
positive cells were counted by ImageJ, single 
blinded and obtained values were plotted in Prism5 
(GraphPad) (n=7/group). 
4. dIscUssION
Our study for the first time showed use of novel 
DHP namely H-DHPM in MCT-induced PAH model. 
We clearly showed here that H-DHPM treatment in 
MCT injected rats significantly improved survival 
and prevented MCT induced PAH development and 
progression. Furthermore, our results affirm, H-DHPM 
precluded progression of pulmonary vascular and 
parenchymal remodelling and prevented right heart 
hypertrophy in H-DHPM treated rats as compared to 
MCT insulted rats. This is the first study of its kind 
that has shown cardio-pulmonary protective effect 
of H-DHPM in MCT induced PAH pathogenesis by 
RVSP, RVH, pulmonary vascular medial thickness 
and pulmonary tissue remodelling assessment.
MCT injected animal have been extensively used to study 
pathogenesis and therapeutic interventions of PAH6,7. The MCT 
animal model of PAH has been reported to be characterised by 
increased pulmonary artery medial wall thickness, vasculitis, 
and RV hypertrophy which ultimately might lead to increased 
mortality6,7. Corroborating previous literature we also observed 
after 3 weeks of MCT injection rats developed significant 
increase in RVSP, medial wall thickness of pulmonary arteries 
(25-200 µm) and RV hypertrophy. Although some studies 
have shown, MCT induces PAH by damaging the pulmonary 
endothelial cells (P-EC)20, however the exact toxicological 
mechanisms of MCT remains elusive. P-EC treated with MCT 
have been shown to develop either intracellular membrane 
disruptions or megalocytosis (characterised by an enlarged 
Figure 5. H-dHPM induces apoptosis in lung parenchyma and lung vasculature 
(a) Representative images of tUNEL assay. (b) Assessment of 
tUNEL+ cells using ImageJ and Prism5 (GraphPad) showed no 
significant difference in percentage of tUNEL+ cells between c 
(2.3 ± 0.51%), Mct (4.17 ± 0.64%), H-dHPM (3.7±1.65) and 
dMsO (3.53 ± 1.85) group lung sections. H-dHPM+Ed (41.56 ± 
5.03), H-dHPM+Ld (37.43 ± 7.09) and dnaseI used as positive 
control (59.36 ± 4.50) showed significant (*p<0.05 vs c) increase in 
tUNEL+ cells as compared to c. scale bar is 50µm,  n=7/group.
(b)
(a)
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Golgi apparatus)6,21. It has also been shown that MCT induced 
injury to vascular endothelium and myocardium results in an 
increase in Endothelin-1 (ET-1) release, a ligand of endothelin 
receptor A (ETA), subsequently leading to pathogenesis of 
PAH.21-23 The ETA receptor is coupled to voltage-dependent 
Ca2+ channels by G-proteins and shown to block Ca2+ channels 
and eventually preventing ETA activation
22,24. Calcium channel 
antagonism relieves injury of the pulmonary endothelium and 
the myocardium and rebalancing an interruption of the reactive 
oxidative species22,24. On the other hand, activation of the L-type 
Ca2+ channels as a consequence of excess ET-1 expression 
results in pulmonary vasculature and the right ventricle 
remodelling20-24. On the contrary, in hypertrophic hearts, 
exogenous ET-1 neither modified right ventricular contractility 
nor systolic or diastolic Ca2+ handling20-24. Intracellular 
Ca2+also acts a secondary messenger and its imbalance can 
induce pulmonary arterial smooth muscle cell (PASMC) 
proliferation25,26. Consequently, it can be interpreted that Ca2+ 
channels play important role in pathogenesis of MCT induced 
PAH. Recently, H-DHPM has been discovered as a versatile 
L-type CCB capable of antiplatelet and antithrombotic activity, 
owing to single acyl (heptanoyl) group at the C4′ position of 
DHPM molecule17,18. In the current study we used 30mg/kg 
dose of H-DHPM to evaluate its effect on PAH pathogenesis. A 
general consensus on the course of PAH pathogenesis dictates 
the pathogenesis of PAH a two phase malady27. First phase 
involves the injury and 2nd phase involves the progression. 
To evaluate if H-DHPM can prevent the early onset and 
the progression of pathogenesis in PAH, we used two study 
protocols, in one group we dosed rats with H-DHPM from day 
zero of MCT injection and in other group we dosed rats with 
H-DHPM from day 14 of MCT injection. In both treatment 
groups we observed significant decrease in RVSP and medial 
wall thickness in comparison to MCT injected animals. These 
observations clearly demonstrated that H-DHPM is protective, 
i.e. it protects the vascular walls from early toxic effects of 
MCT. Of note, H-DHPM when given after 14 days of MCT 
injection not only prevented the progression but reversed the 
effects of MCT as no change was observed in RVSP and medial 
wall thickness of pulmonary arteries (25 µm - 200 µm)in these 
animals. MCT leads to right heart remodelling by directly 
injuring the myocardium and additionally by increasing 
pulmonary vascular resistance through angio-obliterative 
proliferation of medial wall, which has been previously proven 
to be somewhat prevented by different CCBs. Substantiating 
these studies we also observed a decrease in RVH of animals 
treated with H-DHPM as compared to MCT insulted rats. 
Previous studies have shown rats with MCT-induced 
pulmonary hypertension also exhibits a prominent decrease 
in lung compliance, which can be attributed to pulmonary 
parenchymal transdifferentiation, alveolar oedema and 
alveolar septal cell hyperplasia6,28. Since the lung dysfunction 
could exacerbate MCT induced progression of pulmonary 
vascular remodelling, it is essential to evaluate the effect of 
H-DHPM on pulmonary parenchymal tissue in MCT-treated 
rats. We observed a prominent loss of pulmonary parenchymal 
architecture in MCT rats which was markedly prevented by 
H-DHPM treatment in both treatment groups. Additionally, we 
also observed decreased intravascular infiltration, decreased 
alveolar oedema and alveolar septal hyperplasia in rats treated 
with H-DHPM. Moreover, histopathological study has revealed 
MCT-treated animals have marked interstitial hypercellularity 
and fibrosis6. Pulmonary tissues of MCT injected rats have 
excessive collagen secretion and fibrosis.6 Significant increase 
in collagen deposition was observed in our study after 3 weeks 
of MCT exposure. The collagen deposition was prominent in 
remodelled pulmonary parenchyma and vasculature. However, 
early or late treatment both prevented the collagen deposition 
in rat lungs. 
Clinical or experimental studies on PAH have attributed 
the pulmonary vascular pathology to change in cell phenotype, 
pro-angiogenic niche formation and apoptosis resistant 
vascular cells29. Further it’s been shown that these vascular cells 
especially PASMC and P-EC exhibit quasi-cancerous features 
that induce over proliferative demand in these tissues30. On 
the contrary, some studies have reported MCT administration 
results in endothelial injury which triggers the transformation 
of PASMC into more proliferative and apoptosis resistant 
phenotype which could be an explanation of hyperplasia of 
PASMC and lack of plexiform lesions in MCT induced PAH 
animal model31,32. Here we reported, pulmonary sections 
assessed for apoptotic cells by TuNEL assay showed very 
little apoptotic cells in MCT injected animals which was non-
significant to the control animals. However, H-DHPM treatment 
in MCT insulted animals significantly increased number of 
apoptotic cells as compared to in MCT alone insulted animals. 
Interestingly, these TuNEL positive cells were only observed 
in H-DHPM treated MCT animals whereas no apoptotic cells 
were observed in drug alone group. Hence these findings 
clearly suggest that H-DHPM induced apoptosis in diseased 
proliferative cells only that subsequently vetoed vascular 
muscularisation or intimal remodelling, subsequently decreased 
PVR. In addition, we observed H-DHMP induced apoptosis in 
diseased pulmonary tissue and consequently declines fibrino-
proliferative axis hence prevents the development of fibrosis or 
pulmonary alveolar destruction whereas in drug alone groups 
no such apoptotic cells were observed.
NO is a well-known vasodilator and has been used as 
a therapy to treat PAH. It has been speculated that the early 
endothelial damage in MCT animal models is responsible 
for a low level of NO in the pulmonary vessels1,2,6. However, 
a persistent NO is biosynthesised and a sustained release in 
maintained for normal vascular vasodilatation response1,2,6. 
However, under persistent toxic insult of MCT at later stages 
the bioavailability of NO is compromised significantly, 
subsequently resulting in impaired vascular patency. NO 
interacts with Guanylate cyclase via its heme group and 
plays regulatory role in conversion of GTP to cGMP. cGMP 
triggers a reduction in [Ca2+]i concentration through the 
activation of cGMP-dependent protein kinase (PkG)33. This 
mechanism influences smooth muscle cell proliferation, 
hypertrophy, contraction and platelet aggregation related 
PAH pathogenesis33. H-DHPM, arrests biphasic calcium entry, 
thereby eliminating calcium cross talk and suggesting the direct 
stimulatory action of Ca2+-channel blockers on endothelial 
NO production17,18. Further, these studies have proven that 
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H-DHPM improves balance between eNOS/iNOS in both 
preclinical and translational studies. Besides, these studies 
proved the efficacy of H-DHPM was better than amlodipine 
in terms of NO production. Inhibiting platelet aggregation and 
cCGMP; henceforth, projecting H-DHPM as a possible.
The main focus of our study was to identify the beneficial 
effects of novel DHP molecule H-DHPM in MCT-induced 
PAH model. In conclusion, irrespective of the mechanism or 
mechanisms involved, H-DHPM inhibits pulmonary artery 
hypertension and right ventricular hypertrophy in MCT-
treated rats, as well as minimizes the severity of MCT-induced 
morphologic changes in the pulmonary vasculature and 
parenchyma. Notably, H-DHPM not only prevented the early 
onset toxic effects of MCT but also reversed the onset and 
prevented the progression of PAH pathogenesis. 
5. LIMItAtIONs OF tHE stUdy
 This study was intended to assess the role of the H-DHPM, 
a novel DHP compound in preventing the development of 
MCT induced pulmonary hypertension in rats. The major 
limitation of study was not assessing any mechanistic study 
to associate the preventive impact of drug on any particular 
pathway. Since the drug is pleiotropic; its precise mechanism 
of action in prevention of pulmonary hypertension needs to be 
further evaluated in future studies.
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